Sanoculis is an Israel-based company which develops and markets three novel surgical techniques for the treatment of Glaucoma: MIMS® (Minimally Invasive Micro Sclerostomy), inferonasal MIMS® (after failed Trab) and MINT® (Minimally Invasive Nasal Trabeculostomy). These techniques are simple, fast, and minimally invasive.
These techniques require no stitches, eye-patch, implant or stent and thus leave nothing behind. In addition, they can be easily combined with Cataract surgery. These techniques address all Glaucoma patients who need surgery, from mild to severe, using the same stent-less technology.
The MINT® device is a mechanical micro-trephine 0.5 mm long tool which creates a 150 micron in diameter trabeculostomy through the TM. I am happy to announce that MINT is being launched this year and soon you will see its potential to Glaucoma patients.
With the CE certification under MDR now secured for the MINT® device, Sanoculis is actively focusing on expanding into key markets. As part of its market entry strategy, Sanoculis is conducting a Retrospective Real-World Data study in collaboration with leading surgeons from Germany, Spain, Italy and Israel. To date, there are excellent 2-year follow-up MINT® and by June 2025 there will be 3-year follow-up results.